Table 5.
Intraocular pressure reduction after adding brimonidine to the medication regimen of patients already using a prostaglandin analogue.
| n (patients) | Drug | Treatment period | IOP before brimonidine (mmHg) | IOP reduction width (mmHg) | IOP reduction rate (%) | |
|---|---|---|---|---|---|---|
| Brimonidine 0.2% | ||||||
| Lee DA. J Glaucoma. 2001 [12] | 16 | Latanoprost | 2 months | 18.3 | 5.89 | 32.2 |
| Reis R. Clin Ther. 2006 [13] | 16 | Travoprost | 4 weeks | 17.0 ±3.1 | 2.3 ± 1.8 | 13.4 ± 9.1 |
| Brimonidine 0.15% | ||||||
| Konstas AGP. Ophthalmology. 2005 [14] | 29 | Latanoprost | 6 weeks | 19.0 ± 1.7 | 2.2 ± 1.5 | 11.6 |
| Mundorf T. Adv Ther. 2007 [15] | 43 | Latanoprost | 2 months | 21.9 | Peak 5.1 Trough 2.0 |
23 9 |
| Feldman RM. Ophthalmology. 2007 [16] | 79 | Travoprost | 3 months | 21.7 ± 0.33 | 2.1 ± 0.27 | 9.7 |
| Brimonidine 0.1% | ||||||
| Day DG. Curr Med Res Opin. 2008 [17] | 20 | Latanoprost | 3 months | 19.6 ± 2.94 | 3.3 ± 2.82 | 16.8 |
| Araie M. Atarasii Ganka. 2012 [18] | 59 | PG analogues | 52 weeks | 18.7 | 2.7 | 14.4 |
| Yamamoto C. Atarasii Ganka. 2014 [19] | 24 | PG analogues | 3 months | 18.0 ± 2.7 | 2.1 ± 2.2 | 11.8 ± 11.4 |
| Hayashi Y. Rinsho Ganka. 2015 [20] | 17 | PG analogues | 12 months | 11.5 ± 1.5 | 1.5 ± 1.3 | 13.3 ± 10.9 |
| This study (latanoprost or travoprost) | ||||||
| 26 | PG analogues | 12 weeks | 15.8 ± 2.3 | 2.1 ± 2.3 | 12.1 ± 11.8 | |
Data presented as mean ± standard deviation.
IOP, intraocular pressure; PG, prostaglandin.